INVIVYD, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
INVIVYD, INC. (IVVD) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 80.86 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2026-08-13
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-06-30 was 20.83K shares, a 76.05% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-03-31 was 60.03K shares, a 66.23% increase year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-12-31 was 169.16K shares, a 1.68% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2025 was 292.27K shares, a 37.60% decline from fiscal 2024.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2024 was 468.36K shares, a 61.75% decline from fiscal 2023.
- INVIVYD, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2023 was 1.22M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | 20.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 80.86K shares 10-Q · filed 2026-08-13 | 250.02K shares derived: sum of 3 quarters · filed 2026-08-13 | 250.02K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 60.03K shares 10-Q · filed 2026-05-14 | 229.19K shares derived: sum of 2 quarters · filed 2026-05-14 | 229.19K shares derived: sum of 3 quarters · filed 2026-05-14 | 316.19K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | 169.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 169.16K shares derived: sum of 2 quarters · filed 2026-03-05 | 256.16K shares derived: sum of 3 quarters · filed 2026-03-05 | 292.27K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 87.00K shares derived: sum of 2 quarters · filed 2025-11-06 | 123.11K shares 10-Q · filed 2025-11-06 | 295.17K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 87.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 123.11K shares 10-Q · filed 2025-08-14 | 295.17K shares derived: sum of 3 quarters · filed 2025-08-14 | 419.24K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 36.11K shares 10-Q · filed 2025-05-15 | 208.16K shares derived: sum of 2 quarters · filed 2025-05-15 | 332.24K shares derived: sum of 3 quarters · filed 2025-05-15 | |
| 2024-12-31 | 172.05K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 296.13K shares derived: sum of 2 quarters · filed 2025-03-20 | 468.36K shares 10-K · filed 2025-03-20 | |
| 2024-09-30 | 124.08K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 296.30K shares 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 172.22K shares 10-Q · filed 2024-08-14 | |||
| 2023-12-31 | 315.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 545.69K shares derived: sum of 2 quarters · filed 2024-03-28 | 801.13K shares derived: sum of 3 quarters · filed 2024-03-28 | 1.22M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 230.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 485.73K shares derived: sum of 2 quarters · filed 2023-11-09 | 908.93K shares 10-Q · filed 2023-11-09 | 933.93K shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-06-30 | 255.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 678.64K shares 10-Q · filed 2023-08-10 | 703.64K shares derived: sum of 3 quarters · filed 2024-02-09 | 828.64K shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2023-03-31 | 423.20K shares 10-Q · filed 2023-05-11 | 448.20K shares derived: sum of 2 quarters · filed 2024-02-09 | 573.20K shares derived: sum of 3 quarters · filed 2024-02-09 | 671.20K shares derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-12-31 | 25.00K shares derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | 150.00K shares derived: sum of 2 quarters · filed 2024-02-09 | 248.00K shares derived: sum of 3 quarters · filed 2024-02-09 | 298.35K shares 8-K · filed 2024-02-09 |
| 2022-09-30 | 125.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 223.00K shares derived: sum of 2 quarters · filed 2022-11-10 | 273.35K shares 10-Q · filed 2022-11-10 | |
| 2022-06-30 | 98.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 148.35K shares 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | 50.35K shares 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |